NCT06595238CompletedPhase 2
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 262 (actual)
- First submitted
- 11 Sept 2024
- Start date
- 1 Oct 2024
- Primary completion date
- 3 Dec 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Obesity
- NCT number
- NCT06595238
- EU CT number
- 2024-514000-13-00
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 262
- From 1 Oct 2024 to the primary completion date, 3 Dec 2025
- 39 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
- Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
Other illness
- Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
- History of type 1 diabetes mellitus or T2DM
Who the study is looking for
- Adults ≥ 18 years of age
- BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
- A stable body weight for 3 months prior to Screening (±5% body weight change)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (39)
Sites in registry order. Save your city in your profile to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.